Skip to content
ZY Therapeutics
  • Company
    • About Us
    • Executive Team and Advisors
  • ZY-001
    • About ZY-001
    • Etidronate Legacy
    • Novel Formulation
    • Scientific Support
  • Therapeutic Areas
    • Sturge Weber Syndrome
    • Tuberous Sclerosis
    • Neurocysticercosis
    • Fahr’s Disease
  • News & Events
    • News
    • Events
  • Patient Advocacy
  • Contact and Partnership
  • Company
    • About Us
    • Executive Team and Advisors
  • ZY-001
    • About ZY-001
    • Etidronate Legacy
    • Novel Formulation
    • Scientific Support
  • Therapeutic Areas
    • Sturge Weber Syndrome
    • Tuberous Sclerosis
    • Neurocysticercosis
    • Fahr’s Disease
  • News & Events
    • News
    • Events
  • Patient Advocacy
  • Contact and Partnership
Read more about the article Zy Therapeutics at WONOEP 2025: Showcasing Innovation in Epilepsy Research

Zy Therapeutics at WONOEP 2025: Showcasing Innovation in Epilepsy Research

  • Post published:August 1, 2025
  • Post category:Event

- August 30 - September 3, 2025 | Lisbon, Potrugal - Zy Therapeutics is excited to announce that our CMO, Dr. Jeffrey Loeb, will be speaking at the XVIII Workshop…

Continue ReadingZy Therapeutics at WONOEP 2025: Showcasing Innovation in Epilepsy Research
Read more about the article Zy Therapeutics at BIO 2025: Connecting With the Global Biotech Community

Zy Therapeutics at BIO 2025: Connecting With the Global Biotech Community

  • Post published:June 17, 2025
  • Post category:Event

- June 16-19 | Boston - Zy Therapeutics will be present at BIO 2025, one of the world’s leading biotechnology conventions, bringing together innovators, researchers, and industry partners from across…

Continue ReadingZy Therapeutics at BIO 2025: Connecting With the Global Biotech Community
Read more about the article Zy Therapeutics at AES 2024: Advancing Disease-Modifying Treatments

Zy Therapeutics at AES 2024: Advancing Disease-Modifying Treatments

  • Post published:December 5, 2024
  • Post category:Event

- December 6-10, 2024 | Los Angeles, CA - Zy Therapeutics will be attending AES 2024 in Los Angeles to highlight its work toward developing a disease-modifying treatment for Sturge-Weber…

Continue ReadingZy Therapeutics at AES 2024: Advancing Disease-Modifying Treatments
Read more about the article Zy Therapeutics Shares New Data at ASENT 2024

Zy Therapeutics Shares New Data at ASENT 2024

  • Post published:March 12, 2024
  • Post category:News

Zy Therapeutics is presenting new research findings at the American Society for Experimental Neurotherapeutics (ASENT) annual meeting, taking place in Bethesda, MD, from March 12–14, 2024. The team looks forward…

Continue ReadingZy Therapeutics Shares New Data at ASENT 2024
  • Go to the previous page
  • 1
  • 2

A rare disease biotech developing the first therapy to directly target brain calcifications—an overlooked driver of seizures, cognitive decline, and disability in rare CNS disorders.

  • Morristown, New Jersey 07960
Linkedin
  • About Us
  • Executive Team and Advisors
  • About ZY-001
  • Etidronate Legacy
  • Novel Formulation
  • Scientific Support
  • Sturge Weber Syndrome
  • Tuberous Sclerosis
  • Neurocysticercosis
  • Fahr’s Disease
  • News
  • Events
  • Patient Advocacy
  • Contact and Partnership

Legal Policies | Opt-out Preferences

Copyright 2026 Zy Therapeutics | Web by Canis Liberi
ZY Therapeutics
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}